Go to main content

he pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market. This means that the drug, which represents an innovative treatment option for patients afflicted by Essential Thrombocythemia, is available in core Central European markets such as Austria, Hungary, Switzerland, Czech Republic and Poland as well as in Turkey, Israel, Kazakhstan and Russia. “We have started to offer our entire range of products, focusing on rare diseases, in Russia as well as the Middle East,” says Dr. Rudolf Widmann, CEO of AOP Orphan. “These regions are exciting markets, Above all, this way we can open up new treatment possibilities for patients in these countries."

Essential Thrombocythemia (ET) is a rare but serious bone marrow disease, characterized by a significantly elevated blood platelet (thrombocyte) count. This considerably increases the risk of suffering a blood clot or bleeding. In cases of ET where the thrombocytes only function to a limited extent, patients suffer from bleeding in the nose, mouth, stomach and intestines. In other cases where the excessive number of thrombocytes is largely functional, patients carry with them the risk of developing life-threatening thromboses or infarctions.

Thromboreductin® (active ingredient: anagrelide) lowers the blood platelet count and thereby reduces the risk of complications – without the risk of leukemogenesis as is the case with cytostatic agents. If treatment is successful, most patients with Essential Thrombocythemia have an almost normal life expectancy.

About AOP Orphan
AOP Orphan researches, develops, produces and distributes innovative drugs and administration methods to treat rare diseases – and has become a European pioneer in the field of orphan diseases. The company’s focus is on the areas hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases. AOP Orphan is one of the foremost providers in the sector, generating a turnover of more than EUR 60 million as an Austrian company with transnational operations. It has an export ratio of around 70% and employs over 140 people. The rare disease specialist has branch offices situated in its core markets within the EU, Switzerland and the Middle East. The international markets are handled and operated by long-term, close partners of the company. AOP Health has a total of twelve locations.

Further inquiries

AOP Orphan Pharmaceuticals AG
Public Affairs
Wilhelminenstraße 91/2f
1160 Vienna
T +43 1 503 72 44-24
F +43 1 503 72 44-5
M office@aoporphan.com